# RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)

> **NCT04571970** · PHASE1,PHASE2 · COMPLETED · sponsor: **REGENXBIO Inc.** · enrollment: 6 (actual)

## Conditions studied

- Mucopolysaccharidosis Type II (MPS II)

## Interventions

- **GENETIC:** RGX-121

## Key facts

- **NCT ID:** NCT04571970
- **Lead sponsor:** REGENXBIO Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-11
- **Primary completion:** 2023-05-09
- **Final completion:** 2024-05-23
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571970, "RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome)". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT04571970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*